8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have provided diverse ratings for Intra-Cellular Therapies (NASDAQ:ITCI), ranging from bullish to bearish. The average 12-month price target is now $85.88, up 11.9% from the previous $76.75. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's performance and market dynamics. Intra-Cellular Therapies, a biopharmaceutical company, has shown a notable revenue growth of 50.41% over the past 3 months but struggles with profitability and efficiency metrics.
April 03, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has received mixed analyst ratings, with an updated average 12-month price target of $85.88. The company has experienced significant revenue growth but faces challenges in profitability and efficiency.
The mixed analyst ratings with an upward revision in the price target suggest a positive outlook on the stock's future performance, despite the company's current profitability and efficiency challenges. The significant revenue growth is a strong positive indicator, potentially outweighing concerns about net margin and ROE/ROA metrics in the short term. However, the diversity in analyst opinions indicates uncertainty, which could lead to volatility.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100